

## Chordate's CEO Anders Weilandt presents at the Biostock Investor Meeting on March 16th – In English

**Chordate Medical is one of the medtech companies participating at the Biostock Investor Meeting on March 16th. CEO Anders Weilandt will hold his presentation at 11:00 a.m. and talk about the company's focus in 2023 and beyond. After the presentation, he will answer questions in an interview. The presentation will be in English, and the interview will be held in Swedish.**

Anders will, among other things, talk about the positive results from the recently completed migraine study, as well as the ongoing work to create proof-of-concept in the selected markets.

The event is streamed online on [BioStock's website](#) and [YouTube channel](#).

[Read more about the event](#)

**For more information, please contact:**

Anders Weilandt, CEO

[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)

Cell: +46 733-874277

**About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The K.O.S-treatment has clinically proven efficacy according to scientific studies. The company's products are available via distributors to clinics in the Nordic countries, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

**Attachments**

[Chordate's CEO Anders Weilandt presents at the Biostock Investor Meeting on March 16th – In English](#)